ICOSAVAX

Question 1

RSV and hMPV both belong to the Paramyxoviridae family.

Answer 1

TRUE

Question 2

RSV is a leading cause of severe lower respiratory tract infections in infants.

Answer 2

TRUE

Question 3

The IVX-A12 vaccine is focused in preventing the infection in infants.

Answer 3

FALSE

Question 4

Both RSV and hMPV are DNA viruses.

Answer 4

FALSE

Question 5

RSV has two main glycoproteins: F (fusion) and G (adhesion).

Answer 5

TRUE

Question 6

VLP-based vaccines contain live viral genetic material.

Answer 6

FALSE

Question 7

IVX-A12 is a bivalent vaccine targeting both RSV and hMPV.

Answer 7

TRUE

Question 8

VLPs can activate both innate and adaptive immune responses.

Answer 8

TRUE

Question 9

IVX-A12 uses MF59 as an adjuvant in some formulations.

Answer 9

TRUE

Question 10

The protein F in RSV changes from a prefusion to a postfusion state during infection.

Answer 10

TRUE

Question 11

The prefusion state of the F protein is a weaker antigenic target than the postfusion state.

Answer 11

FALSE

Question 12

RSV and hMPV vaccines target the protein G for neutralization.

Answer 12

FALSE

Question 13

The RSV fusion protein facilitates viral entry into host cells.

Answer 13

TRUE

Question 14

IVX-A12 is currently in phase 3 of clinical trials.

Answer 14

FALSE

Question 15

VLP vaccines mimic the structure of viruses diminishing the infectious capacity.

Answer 15

FALSE

Question 16

VLP-based vaccines do not induce a humoral immune response.

Answer 16

FALSE

Question 17

VLP vaccines require a larger dose compared to soluble protein vaccines.

Answer 17

FALSE

Question 18

RSV is the second leading cause of death in children under one year globally.

Answer 18

TRUE

Question 19

IVX-A12 specifically targets the G protein in RSV and hMPV.

Answer 19

FALSE

Question 20

The use of prefusion-stabilized F proteins in vaccines has significantly improved their efficacy.

Answer 20

TRUE